Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD13-02 in Relapsed/Refractory Severe Aplastic Anemia
NCT06622694Phase 1Suspended
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD13-02 in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence of dose-limiting toxicities, serious adverse events, and other treatment-emergent adverse events. Started Jun 2025; status: suspended.
02
Drugs
RD13-02
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06622694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622694.